WuXi Biologics (Cayman) akcijos akcijų analizė | Akcijų kaina | Naujienos | 2269.HK | KYG970081173 | A2QJCN

Data	WuXi Biologics (Cayman) Akcijų kaina
2024-09-05	10,07 undefined
2024-09-04	10,11 undefined
2024-09-03	10,04 undefined
2024-09-02	9,93 undefined
2024-08-30	10,20 undefined
2024-08-29	9,79 undefined
2024-08-28	9,57 undefined
2024-08-27	9,79 undefined
2024-08-26	10,01 undefined
2024-08-23	9,37 undefined
2024-08-22	9,53 undefined
2024-08-21	10,40 undefined
2024-08-20	10,71 undefined
2024-08-19	10,91 undefined
2024-08-16	10,80 undefined
2024-08-15	10,40 undefined
2024-08-14	10,28 undefined
2024-08-13	10,77 undefined
2024-08-12	10,83 undefined

Data	WuXi Biologics (Cayman) Pajamos	WuXi Biologics (Cayman) EBIT	WuXi Biologics (Cayman) Pelnas
2029e	47,46 mlrd. undefined	0 undefined	7,61 mlrd. undefined
2028e	40,30 mlrd. undefined	11,64 mlrd. undefined	6,68 mlrd. undefined
2027e	31,63 mlrd. undefined	9,48 mlrd. undefined	6,09 mlrd. undefined
2026e	24,18 mlrd. undefined	6,56 mlrd. undefined	5,35 mlrd. undefined
2025e	21,07 mlrd. undefined	5,58 mlrd. undefined	4,69 mlrd. undefined
2024e	18,46 mlrd. undefined	4,73 mlrd. undefined	4,09 mlrd. undefined
2023	17,03 mlrd. undefined	4,15 mlrd. undefined	3,40 mlrd. undefined
2022	15,27 mlrd. undefined	4,56 mlrd. undefined	4,42 mlrd. undefined
2021	10,29 mlrd. undefined	3,31 mlrd. undefined	3,39 mlrd. undefined
2020	5,61 mlrd. undefined	1,64 mlrd. undefined	1,69 mlrd. undefined
2019	3,98 mlrd. undefined	1,06 mlrd. undefined	1,01 mlrd. undefined
2018	2,53 mlrd. undefined	696,82 mln. undefined	630,59 mln. undefined
2017	1,62 mlrd. undefined	438,92 mln. undefined	252,63 mln. undefined
2016	989,03 mln. undefined	230,05 mln. undefined	141,10 mln. undefined
2015	557,04 mln. undefined	61,40 mln. undefined	44,51 mln. undefined
2014	331,85 mln. undefined	51,57 mln. undefined	41,98 mln. undefined

	Pajamos	EBIT	Pelnas
2014	331,85 mln. CNY	51,57 mln. CNY	41,98 mln. CNY
2015	557,04 mln. CNY	61,40 mln. CNY	44,51 mln. CNY
2016	989,03 mln. CNY	230,05 mln. CNY	141,10 mln. CNY
2017	1,62 mlrd. CNY	438,92 mln. CNY	252,63 mln. CNY
2018	2,53 mlrd. CNY	696,82 mln. CNY	630,59 mln. CNY
2019	3,98 mlrd. CNY	1,06 mlrd. CNY	1,01 mlrd. CNY
2020	5,61 mlrd. CNY	1,64 mlrd. CNY	1,69 mlrd. CNY
2021	10,29 mlrd. CNY	3,31 mlrd. CNY	3,39 mlrd. CNY
2022	15,27 mlrd. CNY	4,56 mlrd. CNY	4,42 mlrd. CNY
2023	17,03 mlrd. CNY	4,15 mlrd. CNY	3,40 mlrd. CNY
2024e	18,46 mlrd. CNY	4,73 mlrd. CNY	4,09 mlrd. CNY
2025e	21,07 mlrd. CNY	5,58 mlrd. CNY	4,69 mlrd. CNY
2026e	24,18 mlrd. CNY	6,56 mlrd. CNY	5,35 mlrd. CNY
2027e	31,63 mlrd. CNY	9,48 mlrd. CNY	6,09 mlrd. CNY
2028e	40,30 mlrd. CNY	11,64 mlrd. CNY	6,68 mlrd. CNY
2029e	47,46 mlrd. CNY	0 CNY	7,61 mlrd. CNY

2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e
0,33	0,56	0,99	1,62	2,53	3,98	5,61	10,29	15,27	17,03	18,46	21,07	24,18	31,63	40,30	47,46
-	68,28	77,56	63,60	56,61	57,18	40,90	83,36	48,38	11,57	8,37	14,12	14,80	30,79	27,43	17,76
37,16	32,32	39,33	40,79	40,13	41,63	45,12	46,92	44,04	40,08	-	-	-	-	-	-
0,12	0,18	0,39	0,66	1,02	1,66	2,53	4,83	6,72	6,83	0	0	0	0	0	0
0,05	0,06	0,23	0,44	0,70	1,06	1,64	3,31	4,56	4,15	4,73	5,58	6,56	9,48	11,64	0
15,41	10,95	23,26	27,07	27,47	26,66	29,29	32,15	29,85	24,35	25,64	26,49	27,14	29,96	28,88	-
0,04	0,04	0,14	0,25	0,63	1,01	1,69	3,39	4,42	3,40	4,09	4,69	5,35	6,09	6,68	7,61
-	7,32	220,45	78,72	150,00	60,79	66,63	100,71	30,46	−23,10	20,24	14,75	14,07	13,85	9,59	14,01
0,96	2,89	2,89	3,48	3,94	4,00	4,21	4,42	4,38	4,35	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

0,01	0,16	0,17	2,06	4,08	6,75	8,48	11,13	8,71	11,24
0,13	0,19	0,29	0,31	0,80	1,37	2,36	3,26	5,14	6,15
0,03	0,09	0,13	0,30	0,30	0,40	0,76	1,59	0,98	0,63
0,06	0,15	0,20	0,34	0,23	0,40	1,08	1,69	2,28	1,77
0,00	0,01	0,04	0,02	0,33	0,75	1,52	1,86	1,35	1,41
0,23	0,60	0,83	3,03	5,75	9,67	14,20	19,53	18,47	21,20
0,40	0,75	1,15	1,78	2,90	6,80	12,87	19,76	25,92	29,94
0	0	0	0,02	0,19	0,45	1,07	2,20	2,71	2,93
0	0	0	0	0	0	87,67	124,49	109,17	165,50
0	0	0	0	331,81	415,85	391,86	600,65	548,78	511,83
0	0	0	0	0	0,19	0,19	1,53	1,53	1,53
2,67	1,61	2,37	18,23	219,97	80,61	150,48	289,21	281,45	296,47
0,41	0,76	1,16	1,82	3,65	7,93	14,76	24,50	31,09	35,38
0,64	1,36	1,98	4,85	9,39	17,60	28,96	44,03	49,56	56,58

0	0	158,00	192,00	202,00	214,00	225,00	235,00	233,00	235,00
0	0	0	3,44	6,65	10,26	15,95	27,04	22,10	24,49
0,37	0,15	0,27	0,59	1,33	2,51	4,41	8,23	13,58	17,61
0	0	0	0	11,80	12,59	211,98	−449,33	−547,49	−735,42
0	0	0	0	0	0	−2,69	−32,51	−92,24	−113,04
0,37	0,15	0,27	4,02	7,99	12,78	20,56	34,80	35,05	41,25
0,15	0,27	0,11	0,14	0,22	0,19	0,65	0,62	0,79	3,59
4,28	37,27	56,34	85,24	142,16	257,04	500,99	781,01	912,85	707,10
0,05	0,44	0,41	0,58	0,96	1,90	2,52	4,63	6,14	5,36
0,05	0,46	0,18	0	0	0,51	0,77	2,12	0	0
0	0	0,05	0	0	0,03	0,06	0,10	1,47	0,73
0,26	1,20	0,80	0,80	1,32	2,87	4,50	8,26	9,32	10,39
0	0	0,90	0	0	1,66	2,50	2,07	2,95	3,83
0	0	5,49	6,82	2,68	24,73	180,89	124,21	132,08	122,54
3,95	8,79	12,56	19,71	77,49	148,89	880,95	876,73	949,46	969,23
0,00	0,01	0,91	0,03	0,08	1,83	3,57	3,07	4,03	4,92
0,26	1,21	1,71	0,82	1,40	4,71	8,06	11,33	13,35	15,31
0,63	1,36	1,98	4,85	9,39	17,49	28,63	46,12	48,40	56,56

2014	2015	2016	2017	2018	2019	2020	2021	2022
0,05	0,07	0,18	0,30	0,74	1,13	1,97	3,99	5,36
42,00	57,00	93,00	87,00	141,00	221,00	303,00	481,00	800,00
0	0	0	0	0	0	0	0	0
−77,00	−43,00	−253,00	−157,00	−297,00	−294,00	−461,00	−1 313,00	−1 560,00
7,00	28,00	66,00	126,00	180,00	154,00	73,00	269,00	943,00
2,00	2,00	30,00	36,00	0	49,00	82,00	83,00	108,00
2,00	3,00	47,00	43,00	52,00	78,00	94,00	349,00	585,00
0,02	0,11	0,08	0,36	0,76	1,21	1,88	3,43	5,54
−51,00	−334,00	−428,00	−670,00	−1 673,00	−3 234,00	−6 024,00	−6 523,00	−5 868,00
−50,00	−336,00	−421,00	−2 213,00	−416,00	−4 493,00	−7 216,00	−9 601,00	−5 908,00
0	−0,00	0,01	−1,54	1,26	−1,26	−1,19	−3,08	−0,04
0	0	0	0	0	0	0	0	0
0	−0,00	0,89	−0,90	0	1,89	0,82	−0,15	−0,30
0	0	0	3,57	3,21	3,53	5,58	8,46	−2,80
0,03	0,38	0,33	2,23	3,21	5,41	6,57	8,21	−2,59
30,00	381,00	−560,00	−440,00	0	−8,00	159,00	−104,00	507,00
0	0	0	0	0	0	0	0	0
0,00	0,15	0,01	0,33	3,58	2,12	0,89	1,91	−2,61
−29,54	−227,21	−346,96	−310,32	−912,23	−2 026,58	−4 143,50	−3 091,86	−326,72
0	0	0	0	0	0	0	0	0

WuXi Biologics (Cayman) Bruto marža	WuXi Biologics (Cayman) Pelnas-martža	WuXi Biologics (Cayman) EBIT marža	WuXi Biologics (Cayman) Pelnas-martža
2029e	40,08 %	0 %	16,04 %
2028e	40,08 %	28,88 %	16,56 %
2027e	40,08 %	29,96 %	19,26 %
2026e	40,08 %	27,14 %	22,13 %
2025e	40,08 %	26,49 %	22,27 %
2024e	40,08 %	25,64 %	22,14 %
2023	40,08 %	24,35 %	19,96 %
2022	44,04 %	29,85 %	28,95 %
2021	46,93 %	32,16 %	32,93 %
2020	45,13 %	29,31 %	30,09 %
2019	41,64 %	26,66 %	25,45 %
2018	40,16 %	27,49 %	24,88 %
2017	40,80 %	27,11 %	15,61 %
2016	39,34 %	23,26 %	14,27 %
2015	32,44 %	11,02 %	7,99 %
2014	37,14 %	15,54 %	12,65 %

	Bruto marža	EBIT marža	Pelnas-martža
2014	37,14 %	15,54 %	12,65 %
2015	32,44 %	11,02 %	7,99 %
2016	39,34 %	23,26 %	14,27 %
2017	40,80 %	27,11 %	15,61 %
2018	40,16 %	27,49 %	24,88 %
2019	41,64 %	26,66 %	25,45 %
2020	45,13 %	29,31 %	30,09 %
2021	46,93 %	32,16 %	32,93 %
2022	44,04 %	29,85 %	28,95 %
2023	40,08 %	24,35 %	19,96 %
2024e	40,08 %	25,64 %	22,14 %
2025e	40,08 %	26,49 %	22,27 %
2026e	40,08 %	27,14 %	22,13 %
2027e	40,08 %	29,96 %	19,26 %
2028e	40,08 %	28,88 %	16,56 %
2029e	40,08 %	0 %	16,04 %

Data	WuXi Biologics (Cayman) Pardavimai vienai akcijai	WuXi Biologics (Cayman) EBIT vienai akcijai	WuXi Biologics (Cayman) Pelnas vienai akcijai
2029e	11,43 undefined	0 undefined	1,83 undefined
2028e	9,70 undefined	0 undefined	1,61 undefined
2027e	7,61 undefined	0 undefined	1,47 undefined
2026e	5,82 undefined	0 undefined	1,29 undefined
2025e	5,07 undefined	0 undefined	1,13 undefined
2024e	4,44 undefined	0 undefined	0,98 undefined
2023	3,92 undefined	0,95 undefined	0,78 undefined
2022	3,49 undefined	1,04 undefined	1,01 undefined
2021	2,33 undefined	0,75 undefined	0,77 undefined
2020	1,33 undefined	0,39 undefined	0,40 undefined
2019	1,00 undefined	0,27 undefined	0,25 undefined
2018	0,64 undefined	0,18 undefined	0,16 undefined
2017	0,47 undefined	0,13 undefined	0,07 undefined
2016	0,34 undefined	0,08 undefined	0,05 undefined
2015	0,19 undefined	0,02 undefined	0,02 undefined
2014	0,34 undefined	0,05 undefined	0,04 undefined

	Pardavimai vienai akcijai	EBIT vienai akcijai	Pelnas vienai akcijai
2014	0,34 CNY	0,05 CNY	0,04 CNY
2015	0,19 CNY	0,02 CNY	0,02 CNY
2016	0,34 CNY	0,08 CNY	0,05 CNY
2017	0,47 CNY	0,13 CNY	0,07 CNY
2018	0,64 CNY	0,18 CNY	0,16 CNY
2019	1,00 CNY	0,27 CNY	0,25 CNY
2020	1,33 CNY	0,39 CNY	0,40 CNY
2021	2,33 CNY	0,75 CNY	0,77 CNY
2022	3,49 CNY	1,04 CNY	1,01 CNY
2023	3,92 CNY	0,95 CNY	0,78 CNY
2024e	4,44 CNY	0 CNY	0,98 CNY
2025e	5,07 CNY	0 CNY	1,13 CNY
2026e	5,82 CNY	0 CNY	1,29 CNY
2027e	7,61 CNY	0 CNY	1,47 CNY
2028e	9,70 CNY	0 CNY	1,61 CNY
2029e	11,43 CNY	0 CNY	1,83 CNY

	Akcijų skaičius
2014	964,00 mln. Aktien
2015	2,89 mlrd. Aktien
2016	2,89 mlrd. Aktien
2017	3,48 mlrd. Aktien
2018	3,94 mlrd. Aktien
2019	4,00 mlrd. Aktien
2020	4,21 mlrd. Aktien
2021	4,42 mlrd. Aktien
2022	4,38 mlrd. Aktien
2023	4,35 mlrd. Aktien
2024e	4,35 mlrd. Aktien
2025e	4,35 mlrd. Aktien
2026e	4,35 mlrd. Aktien
2027e	4,35 mlrd. Aktien
2028e	4,35 mlrd. Aktien
2029e	4,35 mlrd. Aktien

Data	EPS-prognozė	EPS-Faktinis	Pranešimo ketvirtis
2021-12-31	0,36	0,35 (−1,96 %)	2021 Q4
2021-06-30	0,42	0,40 (−4,35 %)	2021 Q2

%	Pavadinimas	Akcijos	Pokytis	Data
3,12748 %	E Fund Management Co. Ltd.	129 894 500	4 307 000	2023-12-31
2,77861 %	The Vanguard Group, Inc.	115 404 789	−421 000	2024-03-31
2,56405 %	BlackRock Institutional Trust Company, N.A.	106 493 469	−19 681 818	2024-03-25
2,26729 %	Baillie Gifford & Co.	94 168 000	−423 000	2024-02-29
14,06561 %	WuXi Biologics Holdings Limited	584 191 133	0	2024-03-28
1,68743 %	Norges Bank Investment Management (NBIM)	70 084 531	7 259 476	2023-12-31
1,38582 %	Hang Seng Investment Management Ltd.	57 557 793	−743 349	2024-03-31
1,31351 %	Schroder Investment Management (Hong Kong) Ltd.	54 554 500	1 422 500	2024-02-29
1,28041 %	Invesco Advisers, Inc.	53 179 673	−210 000	2024-02-29
1,08739 %	BlackRock Asset Management Ireland Limited	45 162 865	2 218 000	2024-03-25
1,05923 %	BlackRock Advisors (UK) Limited	43 993 365	−1 456 000	2024-03-31
1,03252 %	State Street Global Advisors Asia Ltd.	42 883 950	168 021	2023-10-31
0,94688 %	Bosera Asset Management Co., Ltd.	39 327 000	8 251 500	2023-12-31
0,88728 %	Capital Research Global Investors	36 851 778	−165 599 709	2024-03-31
0,79331 %	INVESCO Great Wall Fund Management Co. Ltd.	32 948 635	1 627 000	2023-12-31
0,71609 %	GF Fund Management Co., Ltd.	29 741 500	16 170 000	2023-12-31
0,68752 %	JP Morgan Asset Management	28 555 149	−809 169	2024-04-02
0,68439 %	Zhong Ou Asset Management Co., Ltd.	28 425 169	−180 000	2023-12-31
0,66436 %	Bank of Communications Schroder Fund Management Co., Ltd.	27 592 955	−1 000	2023-12-31
0,60236 %	CPP Investment Board	25 018 000	19 055 000	2023-03-31
0,52539 %	AEGON-INDUSTRIAL Fund Management Co., Ltd.	21 821 254	8 593 454	2023-06-30
0,52198 %	JPMorgan Asset Management (Asia Pacific) Limited	21 679 639	174 639	2024-04-02
0,52077 %	Harvest Fund Management Co., Ltd.	21 629 500	377 500	2023-12-31
0,42272 %	Templeton Asset Management Ltd.	17 557 123	101 763	2024-02-29
0,41962 %	Geode Capital Management, L.L.C.	17 428 000	461 500	2024-02-29
0,40064 %	BlackRock Financial Management, Inc.	16 639 841	−6 055 000	2022-08-10
0,40014 %	Schroder Investment Management Ltd. (SIM)	16 619 302	−7 069 000	2024-02-29
0,39086 %	China Asset Management Co., Ltd.	16 233 500	−3 968 339	2023-12-31
0,33667 %	Hongde Fund Management Co., Ltd.	13 983 149	17 000	2023-12-31
0,32226 %	Artisan Partners Limited Partnership	13 384 462	2 442 500	2023-12-31
0,31765 %	Chen (Zhisheng)	13 193 017	0	2024-03-27
0,31634 %	Wellington Management Company, LLP	13 138 676	293 781	2024-02-29
0,30067 %	Penghua Fund Management Co., Ltd.	12 487 685	858 000	2023-12-31
0,29889 %	UBS Asset Management (Hong Kong) Limited	12 414 000	−69 500	2023-12-31
0,29391 %	China Asset Management (Hong Kong) Limited	12 206 974	1 693 226	2024-03-31
0,27498 %	APG Asset Management N.V.	11 420 801	−3 276 768	2023-09-30
0,26810 %	Allianz Global Investors Asia Pacific Limited	11 135 246	1 241 500	2024-03-31
0,26073 %	Sands Capital Management, LLC	10 829 140	0	2024-03-31
0,24064 %	Schroder Investment Management (Singapore) Ltd.	9 994 500	0	2023-12-31
0,23964 %	Dimensional Fund Advisors, L.P.	9 953 000	0	2024-03-31
0,23450 %	Baillie Gifford Overseas Ltd.	9 739 759	−118 929	2024-02-29
0,23450 %	Amundi Asset Management, SAS	9 739 500	317 500	2024-03-31
0,23036 %	UBS Asset Management (UK) Ltd.	9 567 510	71 500	2024-03-31
0,21343 %	Fidelity Management & Research Company LLC	8 864 355	−22 728 429	2024-02-29
0,21037 %	Nuveen LLC	8 737 181	425 300	2024-03-31
0,20438 %	Carmignac Gestion	8 488 543	0	2024-02-29
0,20368 %	Yinhua Fund Management Co., Ltd.	8 459 500	735 500	2023-12-31
0,20273 %	China Universal Asset Management Co., Ltd.	8 420 200	−143 500	2023-12-31
0,18752 %	ICBC Credit Suisse Asset Management Co. Ltd.	7 788 500	−1 576 500	2023-12-31
0,18134 %	State Street Global Advisors (US)	7 531 673	−125 000	2024-03-31
0,18021 %	Aviva Investors Global Services Limited	7 484 717	−1 303 511	2024-02-29
0,17713 %	Franklin Templeton International Services SARL	7 356 998	629 865	2023-12-31
0,17089 %	JPMorgan Asset Management U.K. Limited	7 097 507	0	2024-03-31
0,16690 %	JPMorgan Asset Management (Taiwan) Limited	6 932 000	1 942 500	2024-02-29
0,16632 %	Northern Trust Global Investments Limited	6 908 000	56 500	2024-02-29
0,15657 %	Credit Suisse Funds AG	6 503 000	−225 000	2024-03-31
0,15559 %	abrdn Investments Limited	6 462 336	−5 286 500	2024-02-29
0,15065 %	Royal London Asset Management Ltd.	6 257 000	0	2023-12-31
0,14967 %	BlackRock Investment Management (UK) Ltd.	6 216 139	0	2024-02-29
0,14697 %	Manulife Investment Management (North America) Limited	6 104 097	−655 000	2024-02-29
0,14606 %	Li (Ge)	6 066 500	831 000	2024-03-28
0,14387 %	Royal London Asset Management (CIS) Limited_NLE	5 975 500	42 500	2023-08-31
0,14307 %	DWS Investment GmbH	5 942 111	−358 562	2024-03-31
0,13652 %	State Street Global Advisors (UK) Ltd.	5 669 954	7	2024-03-31
0,12944 %	China Southern Asset Management Co. Ltd.	5 376 000	35 500	2023-12-31
0,12885 %	BlackRock (Singapore) Limited	5 351 439	1 293 470	2024-03-31
0,12799 %	Capital World Investors	5 316 000	−7 500	2024-03-31
0,12581 %	Schroder Investment Management North America Inc.	5 225 500	630 500	2024-02-29
0,11922 %	Amundi Japan Ltd.	4 951 500	−41 000	2024-03-31
0,11340 %	HSBC Global Asset Management (UK) Limited	4 709 970	76 921	2024-02-29
0,10777 %	DWS Investments UK Limited	4 475 921	44 615	2024-03-31
0,10614 %	Allspring Global Investments, LLC	4 408 500	−551 500	2024-02-29
0,10496 %	Charles Schwab Investment Management, Inc.	4 359 474	−119 000	2024-03-31
0,09988 %	HuaAn Fund Management Co., Ltd.	4 148 500	−810 000	2023-12-31
0,09770 %	Mediolanum International Funds Limited	4 058 000	−1 067 500	2023-12-31
0,09739 %	China Merchants Fund Management Co. Ltd.	4 044 772	376 000	2023-12-31
0,09509 %	Harding Loevner LP	3 949 500	0	2023-10-31
0,09014 %	California State Teachers Retirement System	3 743 838	−2 233 900	2023-06-30
0,08927 %	Baring Asset Management Ltd.	3 707 500	0	2024-02-29
0,08789 %	Public Mutual Berhad	3 650 304	−2 640 901	2023-10-31
0,08620 %	Huatai-PineBridge Fund Management Co., Ltd.	3 580 049	266 712	2023-12-31
0,08423 %	AEGON Investment Management B.V.	3 498 337	2 009 552	2023-12-31
0,07921 %	Fullgoal Fund Management Co., Ltd.	3 289 898	1 008 127	2023-12-31
0,07830 %	UBS Asset Management (Switzerland)	3 252 000	−219 000	2024-02-29
0,07763 %	OrbiMed Advisors, LLC	3 224 100	0	2023-12-31
0,07551 %	Martin Currie Investment Management Ltd.	3 136 000	1 095 500	2024-02-29
0,07534 %	American Century Investment Management, Inc.	3 129 000	74 500	2024-03-31
0,07422 %	Edmond de Rothschild Asset Management (France) S.A.	3 082 451	104 404	2023-12-31
0,07300 %	Chautauqua Capital Management, LLC	3 031 983	338 735	2023-12-31
0,07270 %	Mellon Investments Corporation	3 019 400	−804 500	2024-03-31
0,07246 %	First Seafront Fund Management Co., Ltd.	3 009 500	2 881 500	2023-12-31
0,07159 %	Bank of China Investment Management Co., Ltd.	2 973 500	111 000	2023-12-31
0,07147 %	Mirae Asset Global Investments (Hong Kong) Limited	2 968 202	784 713	2024-03-31
0,07041 %	Bellevue Asset Management AG	2 924 500	−2 107 000	2024-02-29
0,06875 %	Barings (U.K.) Limited	2 855 500	1 043 000	2023-12-31
0,06756 %	Huashang Fund Management Co., Ltd.	2 806 001	93 500	2023-12-31
0,06606 %	PGGM Vermogensbeheer B.V.	2 743 626	−68 502	2023-07-31
0,06582 %	Fideuram Asset Management (Ireland) dac	2 733 800	13 500	2024-02-29
0,06501 %	HSBC Global Asset Management (Hong Kong) Limited	2 700 099	−673 000	2024-02-29
0,06501 %	Matthews International Capital Management, L.L.C.	2 700 000	0	2024-02-29

Pavadinimas	Santykis	Dviejų savaičių koreliacija	Vieno mėnesio koreliacija	Trymėnesio koreliacija	Šešių mėnesių koreliacija	Vienmečio koreliacija	Dviejų metų koreliacija
Amicus Therapeutics	TiekėjasKlientas	0,87	0,16	0,22	0,70	0,57	-0,19
ABL Bio	TiekėjasKlientas	0,80	0,69	0,39	0,04	-0,65	-0,76
Sino Biopharmaceutical	TiekėjasKlientas	0,80	0,47	0,69	0,78	0,87	-0,04
Legochem Biosciences	TiekėjasKlientas	0,73	0,82	0,23	0,60	0,65	0,10
AC Immune	TiekėjasKlientas	0,68	0,77	0,42	0,79	0,92	0,49
Oncorus	TiekėjasKlientas	0,67	0,35	0,46	0,91	0,92	-
Antengene Corp Rg	TiekėjasKlientas	0,65	0,09	0,54	0,90	0,92	-
Cullinan Oncology	TiekėjasKlientas	0,65	0,49	0,23	0,72	0,91	-
Vir Biotechnology	TiekėjasKlientas	0,60	0,08	-0,02	0,86	0,77	0,41
Citigroup	TiekėjasKlientas	0,44	0,25	0,35	0,59	0,80	0,76

What values and corporate philosophy does WuXi Biologics (Cayman) represent?

WuXi Biologics (Cayman) Inc represents a strong set of values and a clear corporate philosophy. The company is committed to enabling global partners to develop and manufacture biologics efficiently and cost-effectively. WuXi Biologics is driven by a customer-centric approach, providing integrated solutions and the highest quality services to meet the diverse needs of its clients. With a focus on innovation, WuXi Biologics embraces cutting-edge technologies and invests in state-of-the-art facilities to ensure world-class bio-manufacturing capabilities. This dedication to excellence, along with a commitment to collaboration and integrity, positions WuXi Biologics as a trusted and leading player in the biopharmaceutical industry.

In which countries and regions is WuXi Biologics (Cayman) primarily present?

WuXi Biologics (Cayman) Inc is primarily present in China, with its headquarters in Shanghai. However, the company also has a global presence, with operations and facilities in multiple countries and regions. These include the United States, Germany, Ireland, Singapore, and China's Suzhou, Wuxi, and Hangzhou cities. With its international reach, WuXi Biologics (Cayman) Inc is well-positioned to cater to the global demand for biologics development, manufacturing, and supply chain solutions.

What significant milestones has the company WuXi Biologics (Cayman) achieved?

WuXi Biologics (Cayman) Inc, a leading global open-access biologics technology platform company, has achieved significant milestones since its inception. The company has rapidly expanded its capabilities and established strategic partnerships with global pharmaceutical giants. WuXi Biologics has successfully developed and launched numerous innovative biologics products, providing customized and high-quality solutions to its clients. Moreover, the company has received numerous accolades and recognition for its outstanding performance and contributions to the biopharmaceutical industry. Through its dedication to innovation and commitment to excellence, WuXi Biologics (Cayman) Inc continues to revolutionize the biologics landscape and drive advancements in healthcare.

What is the history and background of the company WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) Inc, founded in 2011, is a leading global open-access Biologics technology platform company. It offers end-to-end solutions for biologics discovery, development, and manufacturing to support worldwide partners in advancing biologics through various stages of development. With state-of-the-art facilities and a team of experienced professionals, WuXi Biologics leverages its expertise in cell line development, process development, and biologics manufacturing to offer cost-effective and high-quality services. The company's commitment to innovation, quality, and customer satisfaction has propelled its rapid growth and success in the biopharmaceutical industry. WuXi Biologics (Cayman) Inc is dedicated to enabling global healthcare by providing access to biologics for patients worldwide.

Who are the main competitors of WuXi Biologics (Cayman) in the market?

The main competitors of WuXi Biologics (Cayman) Inc in the market include companies such as Lonza Group Ltd., Catalent Inc., and Samsung Biologics Co., Ltd.

In which industries is WuXi Biologics (Cayman) primarily active?

WuXi Biologics (Cayman) Inc primarily operates in the biopharmaceutical industry.

What is the business model of WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) Inc. operates as a global open-access biologics technology platform company. It provides a comprehensive range of services in discovery, development, and manufacturing of biologics. The company's business model focuses on offering end-to-end solutions to global pharmaceutical and biotech companies. WuXi Biologics offers integrated services encompassing cell line development, process development, analytical development, and biologics manufacturing, including clinical and commercial manufacturing. By providing high-quality and cost-effective solutions, WuXi Biologics has established itself as a leading player in the biologics industry, enabling its clients to accelerate their drug development programs and reduce manufacturing costs.

Koks yra WuXi Biologics (Cayman) 2024 KGV?

WuXi Biologics (Cayman) KGV yra 10,71.

Koks WuXi Biologics (Cayman) 2024 KUV?

WuXi Biologics (Cayman) KUV yra 2,37.

Koks yra WuXi Biologics (Cayman) AlleAktien kokybės įvertinimas?

AlleAktien kokybės įvertis WuXi Biologics (Cayman) yra 4/10.

Koks yra WuXi Biologics (Cayman) 2024 pajamų dydis?

tikėtina WuXi Biologics (Cayman) pardavimai yra 18,46 mlrd. CNY.

Kokia yra WuXi Biologics (Cayman) 2024 pelnas?

tikėtina WuXi Biologics (Cayman) pelnas yra 4,09 mlrd. CNY.

Ką daro WuXi Biologics (Cayman)?

The company WuXi Biologics (Cayman) Inc is a worldwide leading provider of end-to-end solutions in the biopharmaceutical industry. The company specializes in the manufacturing of biological drugs and offers a wide range of services, from research and development to manufacturing and marketing of products. WuXi Biologics' business model is divided into three main areas: 1. Research and Development: The company offers a comprehensive range of services for biopharmaceutical research and development, including protein and antibody structure elucidation, biomarker identification, cell line development, and small molecule production. WuXi Biologics aims to support its customers in accelerating their research process, thereby shortening the timeframe for product availability in the market. 2. Manufacturing: WuXi Biologics is one of the world's largest providers of manufacturing services for biological drugs. The company has a broad range of technologies and capabilities to meet its customers' requirements, from non-clinical to commercial product manufacturing. WuXi Biologics' production facilities are certified by the FDA or EMA, and the company strives to meet the highest standards in production and compliance with quality controls. 3. Marketing and Distribution: WuXi Biologics also offers marketing and distribution services for biological drugs, including support in product launch and management of distribution networks. The company has an experienced team of industry analysts, market researchers, and sales experts who help customers maximize their market presence and increase profits. The products offered by WuXi Biologics include biologicals, small molecules, and sample preparation, such as antibodies, peptides, recombinant proteins, and oligonucleotides. The company also provides platform technologies such as CHO-S production, plasmid manufacturing, virus production, proteomic analysis, and clinical diagnostics. With its innovative technologies, wide range of services, and ability to collaborate with customers worldwide, WuXi Biologics has firmly established its reputation as a leading company in the biopharmaceutical industry.

Kokia yra WuXi Biologics (Cayman) dividendė?

WuXi Biologics (Cayman) moka dividendą 0 CNY, kuris yra paskirstytas per išmokas per metus.

Kiek kartų WuXi Biologics (Cayman) moka dividendą?

Dividenda šiuo metu negali būti apskaičiuota WuXi Biologics (Cayman) arba įmonė dividendų nemoka.

Kas yra WuXi Biologics (Cayman) ISIN?

WuXi Biologics (Cayman) ISIN yra KYG970081173.

Kas yra WuXi Biologics (Cayman) WKN?

WuXi Biologics (Cayman) WKN yra A2QJCN.

Kas yra WuXi Biologics (Cayman) Tickeris?

WuXi Biologics (Cayman) akcijų simbolis yra 2269.HK.

Kiek dividendų moka WuXi Biologics (Cayman)?

Per paskutinius 12 mėnesių WuXi Biologics (Cayman) išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams WuXi Biologics (Cayman) tikėtina išmokės dividendus, kurie sudarys 0 CNY.

Kokia yra WuXi Biologics (Cayman) dividendų grąža?

WuXi Biologics (Cayman) šiuo metu yra dydžio dividendų grąža.

Kada WuXi Biologics (Cayman) moka dividendus?

WuXi Biologics (Cayman) moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Kokia saugi yra WuXi Biologics (Cayman) dividendų išmokėjimas?

WuXi Biologics (Cayman) per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Kokia yra WuXi Biologics (Cayman) dividendų suma?

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 CNY. Tai atitinka 0 % dividendų grąžos procentą.

Kokiame sektoriuje yra WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) priskiriamas sektoriui "Sveikata".

Wann musste ich die Aktien von WuXi Biologics (Cayman) kaufen, um die vorherige Dividende zu erhalten?

Norėdamas gauti paskutinį WuXi Biologics (Cayman) dividendą nuo 2024-09-09, kurio dydis yra 0 CNY, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-09-09.

Kada WuXi Biologics (Cayman) paskutinį kartą mokėjo dividendą?

Paskutinės dividendų išmokėjimas įvyko 2024-09-09.

Kokia buvo WuXi Biologics (Cayman) dividendų suma 2023 metais?

2023 metais WuXi Biologics (Cayman) išmokėjo 0 CNY dividendų.

Kokia valiuta WuXi Biologics (Cayman) moka dividendus?

WuXi Biologics (Cayman) dividendai yra mokami CNY.

Tiesioginiai išleidimai	33 762
Netiesioginės emisijos iš įsigytos energijos	136 067
Tiesioginiai išmetimai iš vertybių grandinės	—
CO₂ emisijos	169 829
CO₂ mažinimo strategija	✅
Anglies energija	❌
Atomkraft	❌
Bandymai su gyvūnais	✅
Pelz & Leder	—
Pesticidai	—
Palmių aliejus	—
Tabakas	❌
Genetinė inžinerija	❌
Klimato koncepcija	—
Tvarioji miškininkystė	—
Perdirbimo nuostatai	✅
Aplinkai draugiška pakuotė	✅
Pavojingosios medžiagos	✅
Degalų sąnaudos ir efektyvumas	❌
Vandens suvartojimas ir efektyvumas	✅

Moterų dalis tarp darbuotojų	53
Moterų dalis valdyme	—
Azijietiškų darbuotojų dalis	—
Akcijų dalis Azijos valdyme	—
Hispanų/lotynų kilmės darbuotojų dalis	—
Hispanų/latino kilmės vadybos dalis	—
Akcijų turimų tamsios odos darbuotojų procentas	—
Juodaodžių valdymo dalis	—
Baltųjų darbuotojų dalis	—
Baltųjų valdymo dalis	—
Suaugusiųjų turinys	❌
Alkoholis	❌
Ginkluotė	—
Šaunamieji ginklai	❌
Azartiniai lošimai	❌
Karinių sutarčių	❌
Žmogaus teisių koncepcija	✅
Privatumo politika	—
Darbo ir sveikatos apsauga	✅
Katalikiškas	✅

Tvarumo ataskaita	✅
Akcijų turėtojų įtraukimas	✅
Atsiliepimo taisyklės	❌
Kartelio teisė	❌

Birža	WuXi Biologics (Cayman) Akcijų kodas
DIUSELDORFAS	1FW2.DU
FRANKFURTAS	1FW2.F
HKSE	2269.HK
MIUNCHENAS	1FW2.MU
PNK	WXIBF

WuXi Biologics (Cayman) Akcijų kodas	WuXi Biologics (Cayman) FIGI
2269:HK	BBG00GTY47H0
1FW2:GR	BBG00GXQDVD3
1FW2:GF	BBG00GXQDVF1
1FW2:GD	BBG00GXQDVG0
1FW2:GS	BBG00GXQDVJ7
1FW2:GM	BBG00GXQDVK5
1FW2:GB	BBG00GXQDVL4
22691EUR:EO	BBG00GXY9799
22691EUR:XH	BBG00GXY97D4
22691EUR:XF	BBG00GXY97G1
22691EUR:XE	BBG00GXY97J8
22691EUR:XJ	BBG00GXY97K6
22691EUR:XL	BBG00GXY97L5
22691EUR:XG	BBG00GXY97M4
22691EUR:XO	BBG00GXY97N3
22691EUR:XA	BBG00GXY97T7
22691EUR:E1	BBG00GXY97V4
22691EUR:XT	BBG00GXY97W3
22691EUR:XW	BBG00GXY97X2
22691EUR:XU	BBG00GXY97Y1
22691EUR:XV	BBG00GXY97Z0
22691EUR:EU	BBG00GXY9815
2269:H2	BBG00HMKDMC7
2269:H1	BBG00HMKF104
WXIBF:US	BBG00HW3DBG4
WXIBF:PQ	BBG00HW3DBV7
WXIBF:UV	BBG00HW3DBW6
22691EUR:XX	BBG00JN8MQX7
2269N:L3	BBG00JRFL1G2
2269N:B3	BBG00JRFRRW1
2269N:PO	BBG00JRFXBK2
22691HKD:EO	BBG00JRGLFK4
22691HKD:XH	BBG00JRGLFN1
22691HKD:XF	BBG00JRGLFQ8
22691HKD:XE	BBG00JRGLFS6
22691HKD:XJ	BBG00JRGLFT5
22691HKD:XL	BBG00JRGLFV2
22691HKD:XG	BBG00JRGLFW1
22691HKD:XO	BBG00JRGLFX0
22691HKD:XA	BBG00JRGLG22
22691HKD:E1	BBG00JRGLG31
22691HKD:XT	BBG00JRGLG40
22691HKD:XW	BBG00JRGLG59
22691HKD:XU	BBG00JRGLG68
22691HKD:XV	BBG00JRGLG77
22691HKD:XM	BBG00JRGLG86
22691HKD:XQ	BBG00JRGLGB2
22691HKD:XX	BBG00JRGLGC1
22691HKD:XZ	BBG00JRGLGD0
22691HKD:EU	BBG00JRGLGG7
1FW:TH	BBG00L2RGBR0
22691HKD:X2	BBG00Q6SHJ59
1FW2:GZ	BBG00SSL1SB6
22691EUR:EP	BBG00SSQ7DN9
22691EUR:EZ	BBG00SSQ7DQ6
1FW2:QT	BBG00WR8TN37
2963N:L1	BBG00YB09YT7
2269N:MM	BBG00YG35MP0
2269N:MF	BBG00YG35MQ9
2269N:MU	BBG00YG35MR8
22691USD:EO	BBG00Z6CPDN8
22691USD:XH	BBG00Z6CPDR4
22691USD:XF	BBG00Z6CPDT2
22691USD:XE	BBG00Z6CPDW8
22691USD:XJ	BBG00Z6CPDX7
22691USD:XL	BBG00Z6CPDY6
22691USD:XG	BBG00Z6CPDZ5
22691USD:XO	BBG00Z6CPF08
22691USD:XA	BBG00Z6CPF44
22691USD:XT	BBG00Z6CPF62
22691USD:XW	BBG00Z6CPF71
22691USD:XU	BBG00Z6CPF80
22691USD:XV	BBG00Z6CPFB6
22691USD:XM	BBG00Z6CPFC5
22691USD:EU	BBG00Z6CPFL5
1FW2:LA	BBG018H9J6S9
1FW2:LU	BBG018J357J3

Padaryk geriausias savo gyvenimo investicijas fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Kursas

Akcijos kaina

Akcijų kodas2269.HK

ISINKYG970081173

VVPA2QJCN

WuXi Biologics (Cayman) akcijų kaina

Kursas

Apžvalga

Intraday funkcija

Bendroji grąža ir santykinė kainų pokyčiai

Interpretacija ir investavimas

WuXi Biologics (Cayman) Akcijų istorija

WuXi Biologics (Cayman) akcijų apyvarta, EBIT, pelnas KYG970081173 · A2QJCN

Pajamos, pelnas & EBIT

Supratimas apie pajamas, EBIT ir pelną

Metinė analizė ir palyginimai

Išnaudoti lūkesčius investuojant

Investicijų įžvalgos

WuXi Biologics (Cayman) Pajamų, pelno ir EBIT istorija.

WuXi Biologics (Cayman) Akcijų rodikliai

GuV

Pajamos ir augimas

Bruto marža

EBIT ir EBIT marža

Pajamos ir jų augimas

Leidžiamų akcijų skaičius

Metinių duomenų palyginimo interpretacija

Lūkesčiai ir prognozės

Balansas

Balanso supratimas

Turtas

Įsipareigojimai

Nuosavas kapitalas

Metų po metų analizė

Duomenų interpretacija

WuXi Biologics (Cayman) Akcijos Maržos KYG970081173 · A2QJCN

Margen

Supratimas apie bruto maržą

EBIT maržos analizė

Pardavimų maržos įžvalgos

Lūkesčių interpretavimas

Lyginamoji analizė

WuXi Biologics (Cayman) Maržų istorija

WuXi Biologics (Cayman) akcijos apyvarta, EBIT, pelnas vienai akcijai KYG970081173 · A2QJCN

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

WuXi Biologics (Cayman) Pardavimų, pelno ir EBIT istorija vienai akcijai

WuXi Biologics (Cayman) akcija ir akcijų analizė

WuXi Biologics (Cayman) vertinimas pagal Fair Value

Fair Value

Supratimas apie Fair Value

Pajamų pagrindu skaičiuojamas Fair Value

Apyvartos pagrindu skaičiuojamas Fair Value

Dividendų pagrindu skaičiuojamas Fair Value

Lūkesčiai ir prognozės

Palyginamoji analizė

WuXi Biologics (Cayman) įvertinimas pagal istorinį P/E, EBIT ir P/S

WuXi Biologics (Cayman) akcijų skaičius KYG970081173 · A2QJCN

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

WuXi Biologics (Cayman) Akcijų padalijimai

WuXi Biologics (Cayman) Pelno prognozės

WuXi Biologics (Cayman) Pelnų staigmenos

Eulerpool ESG reitingas WuXi Biologics (Cayman) akcijai

Eulerpool World ESG Rating (EESG©)

96/ 100

🌱 Environment

👫 Social

🏛️ Governance

Aplinka (Environment)

Socialinis (Social)

Įmonės valdymas (Governance)

WuXi Biologics (Cayman) akcijos akcininkų struktūra

Padaryk geriausias savo gyvenimo investicijas
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Akcijų kodas
2269.HK

ISIN
KYG970081173

VVP
A2QJCN